SRGN

Across TCGA pan-cancer cohorts, SRGN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SRGN data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SRGN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SRGN expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where SRGN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	0.839	0.540	.033	7	view →
LUAD	OS	Quartile	All	0.928	1.000	.019	5	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
CCRCC	DFS	Tertile	II,III,IV	0.782	0.232	.038	2	view →
LSCC	DFS	Quartile	All	0.799	0.331	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SRGN–HNSC (DFS)

Open the HNSC breakdown →